Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells

Cornelia Siebenkäs, Katherine B. Chiappinelli, Angela A. Guzzetta, Anup Sharma, Jana Jeschke, Rajita Vatapalli, Stephen B. Baylin, Nita Ahuja

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Innovative therapies for solid tumors are urgently needed. Recently, therapies that harness the host immune system to fight cancer cells have successfully treated a subset of patients with solid tumors. These responses have been strong and durable but observed in subsets of patients. Work from our group and others has shown that epigenetic therapy, specifically inhibiting the silencing DNA methylation mark, activates immune signaling in tumor cells and can sensitize to immune therapy in murine models. Here we show that colon and ovarian cancer cell lines exhibit lower expression of transcripts involved in antigen processing and presentation to immune cells compared to normal tissues. In addition, treatment with clinically relevant low doses of DNMT inhibitors (that remove DNA methylation) increases expression of both antigen processing and presentation and Cancer Testis Antigens in these cell lines. We confirm that treatment with DNMT inhibitors upregulates expression of the antigen processing and presentation molecules B2M, CALR, CD58, PSMB8, PSMB9 at the RNA and protein level in a wider range of colon and ovarian cancer cell lines and treatment time points than had been described previously. In addition, we show that DNMTi treatment upregulates many Cancer Testis Antigens common to both colon and ovarian cancer. This increase of both antigens and antigen presentation by epigenetic therapy may be one mechanism to sensitize patients to immune therapies.

Original languageEnglish (US)
Article numbere0179501
JournalPloS one
Volume12
Issue number6
DOIs
StatePublished - Jun 2017
Externally publishedYes

Fingerprint

ovarian neoplasms
Testicular Neoplasms
Antigen Presentation
DNA methylation
DNA Methylation
colorectal neoplasms
Ovarian Neoplasms
Colonic Neoplasms
Machinery
testes
Cells
antigens
Antigens
therapeutics
neoplasms
Processing
Tumors
cell lines
epigenetics
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. / Siebenkäs, Cornelia; Chiappinelli, Katherine B.; Guzzetta, Angela A.; Sharma, Anup; Jeschke, Jana; Vatapalli, Rajita; Baylin, Stephen B.; Ahuja, Nita.

In: PloS one, Vol. 12, No. 6, e0179501, 06.2017.

Research output: Contribution to journalArticle

Siebenkäs, Cornelia ; Chiappinelli, Katherine B. ; Guzzetta, Angela A. ; Sharma, Anup ; Jeschke, Jana ; Vatapalli, Rajita ; Baylin, Stephen B. ; Ahuja, Nita. / Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. In: PloS one. 2017 ; Vol. 12, No. 6.
@article{3bf0996a016c4aa9bc63668872040310,
title = "Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells",
abstract = "Innovative therapies for solid tumors are urgently needed. Recently, therapies that harness the host immune system to fight cancer cells have successfully treated a subset of patients with solid tumors. These responses have been strong and durable but observed in subsets of patients. Work from our group and others has shown that epigenetic therapy, specifically inhibiting the silencing DNA methylation mark, activates immune signaling in tumor cells and can sensitize to immune therapy in murine models. Here we show that colon and ovarian cancer cell lines exhibit lower expression of transcripts involved in antigen processing and presentation to immune cells compared to normal tissues. In addition, treatment with clinically relevant low doses of DNMT inhibitors (that remove DNA methylation) increases expression of both antigen processing and presentation and Cancer Testis Antigens in these cell lines. We confirm that treatment with DNMT inhibitors upregulates expression of the antigen processing and presentation molecules B2M, CALR, CD58, PSMB8, PSMB9 at the RNA and protein level in a wider range of colon and ovarian cancer cell lines and treatment time points than had been described previously. In addition, we show that DNMTi treatment upregulates many Cancer Testis Antigens common to both colon and ovarian cancer. This increase of both antigens and antigen presentation by epigenetic therapy may be one mechanism to sensitize patients to immune therapies.",
author = "Cornelia Siebenk{\"a}s and Chiappinelli, {Katherine B.} and Guzzetta, {Angela A.} and Anup Sharma and Jana Jeschke and Rajita Vatapalli and Baylin, {Stephen B.} and Nita Ahuja",
year = "2017",
month = "6",
doi = "10.1371/journal.pone.0179501",
language = "English (US)",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells

AU - Siebenkäs, Cornelia

AU - Chiappinelli, Katherine B.

AU - Guzzetta, Angela A.

AU - Sharma, Anup

AU - Jeschke, Jana

AU - Vatapalli, Rajita

AU - Baylin, Stephen B.

AU - Ahuja, Nita

PY - 2017/6

Y1 - 2017/6

N2 - Innovative therapies for solid tumors are urgently needed. Recently, therapies that harness the host immune system to fight cancer cells have successfully treated a subset of patients with solid tumors. These responses have been strong and durable but observed in subsets of patients. Work from our group and others has shown that epigenetic therapy, specifically inhibiting the silencing DNA methylation mark, activates immune signaling in tumor cells and can sensitize to immune therapy in murine models. Here we show that colon and ovarian cancer cell lines exhibit lower expression of transcripts involved in antigen processing and presentation to immune cells compared to normal tissues. In addition, treatment with clinically relevant low doses of DNMT inhibitors (that remove DNA methylation) increases expression of both antigen processing and presentation and Cancer Testis Antigens in these cell lines. We confirm that treatment with DNMT inhibitors upregulates expression of the antigen processing and presentation molecules B2M, CALR, CD58, PSMB8, PSMB9 at the RNA and protein level in a wider range of colon and ovarian cancer cell lines and treatment time points than had been described previously. In addition, we show that DNMTi treatment upregulates many Cancer Testis Antigens common to both colon and ovarian cancer. This increase of both antigens and antigen presentation by epigenetic therapy may be one mechanism to sensitize patients to immune therapies.

AB - Innovative therapies for solid tumors are urgently needed. Recently, therapies that harness the host immune system to fight cancer cells have successfully treated a subset of patients with solid tumors. These responses have been strong and durable but observed in subsets of patients. Work from our group and others has shown that epigenetic therapy, specifically inhibiting the silencing DNA methylation mark, activates immune signaling in tumor cells and can sensitize to immune therapy in murine models. Here we show that colon and ovarian cancer cell lines exhibit lower expression of transcripts involved in antigen processing and presentation to immune cells compared to normal tissues. In addition, treatment with clinically relevant low doses of DNMT inhibitors (that remove DNA methylation) increases expression of both antigen processing and presentation and Cancer Testis Antigens in these cell lines. We confirm that treatment with DNMT inhibitors upregulates expression of the antigen processing and presentation molecules B2M, CALR, CD58, PSMB8, PSMB9 at the RNA and protein level in a wider range of colon and ovarian cancer cell lines and treatment time points than had been described previously. In addition, we show that DNMTi treatment upregulates many Cancer Testis Antigens common to both colon and ovarian cancer. This increase of both antigens and antigen presentation by epigenetic therapy may be one mechanism to sensitize patients to immune therapies.

UR - http://www.scopus.com/inward/record.url?scp=85020942049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020942049&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0179501

DO - 10.1371/journal.pone.0179501

M3 - Article

C2 - 28622390

AN - SCOPUS:85020942049

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e0179501

ER -